Potential applications of small interfering RNAs in the cardiovascular field

Drugs of the Future

Volumn 31, Issue 6, 2006, Pages 513-525

  Agostini, F ^a   Dapas, B ^a   Farra, R ^a   Grassi, M ^b   Racchi, G ^c   Klingel, K ^c   Kandolf, R ^c   Heidenreich, O ^d   Mercatanti, A ^e   Rainaldi, G ^e   Altamura, N ^a   Guarnieri, G ^a   Grassi, G ^a,c  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLODEXTRIN DERIVATIVE; FLICE INHIBITORY PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; MACROGOL; MICRORNA; PHOSPHOLAMBAN; PLASMID DNA; POLYASPARTIC ACID; POLYETHYLENEIMINE; POLYHYDROXYPROPYLMETHACRYLIC ACID; POLYMER; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; MAMMAL CELL; MEDICAL RESEARCH; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA INTERFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE; VIRUS MYOCARDITIS;

EID: 33748782549     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.06.995893     Document Type: Review

References (86)

1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806-11.
2. Hannon, G.J., Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431: 371-8.
3. Meister, G., Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431: 343-9.
4. Ambros, V. The functions of animal microRNAs. Nature 2004, 431: 350-5.
5. Matzke, M.A., Birchler, J.A. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005, 6: 24-35.
6. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411: 494-8.
7. Martinez, L.A., Naguibneva, I., Lehrmann, H. et al. Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002, 99: 14849-54.
8. Smolic, R., Volarevic, M., Wu, C.H., Wu, G.Y. Potential applications of siRNA in hepatitis C virus therapy. Curr Opin Invest Drugs 2006, 7: 142-6.
9. Sledz, C.A., Williams, B.R. RNA interference in biology and disease. Blood 2005, 106: 787-94.
10. Uprichard, S.L. The therapeutic potential of RNA interference. FEBS Lett 2005, 579: 5996-6007.
11. Zentilin, L., Giacca, M. In vivo transfer and expression of genes coding for short interfering RNAs. Curr Pharm Biotechnol 2004, 5: 341-7.
12. Poliseno, L., Evangelista, M., Mercatanti, A., Mariani, L., Citti, L., Rainaldi, G. The energy profiling of short interfering RNAs is highly predictive of their activity. Oligonucleotides 2004, 14: 227-32.
13. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S., Khvorova, A. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22: 326-30.
14. Hammond, S.M. Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett 2005, 579: 5822-9.
15. Novina, C.D., Sharp, P.A. The RNAi revolution. Nature 2004, 430: 161-4.
16. Sharp, P.A. RNA interference - 2001. Genes Dev 2001, 15: 485-90.
17. Elbashir, S.M., Lendeckel, W., Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15: 188-200.
18. Lee, S.H., Sinko, P.J. siRNA - Getting the message out. Eur J Pharm Sci 2006, 27: 401-10.
19. Rozema, D., Lewis, D. siRNA delivery technologiesa for mammalian systems. Targets 2003, 2: 253-60.
20. Chen, D., Murphy, B., Sung, R., Bromberg, J.S. Adaptive and innate immune responses to gene transfer vectors: Role of cytokines and chemokines in vector function. Gene Ther 2003, 10:991-8.
21. Luo, D., Saltzman, W.M. Synthetic DNA delivery systems. Nat Biotechnol 2000, 18: 33-7.
22. McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., Kay, M.A. RNA interference in adult mice. Nature 2002, 418: 38-9.
23. Liu, F., Song, Y., Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6: 1258-66.
24. Ludtke, J.J., Zhang, G., Sebestyen, M.G., Wolff, J.A. A nuclear localization signal can enhance both the nuclear transport and expression of 1 kb DNA. J Cell Sci 1999, 112(Pt. 12): 2033-41.
25. Chollet, P., Favrot, M.C., Hurbin, A., Coll, J.L. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002, 4: 84-91.
26. Pun, S.H., Davis, M.E. Development of a non viral gene delivery vehicle for systemic application. Bioconjug Chem 2002, 13: 630-9.
27. Decher, G. Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science 1997, 277: 1232-7.
28. Heyes, J., Palmer, L., Bremner, K., MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005, 107: 276-87.
29. Heidel, J.D., Hu-Lieskovan, S., Bartlett, D.W., Triche, T.J., Davis, M. E. Systemic administration of siRNA against EWS-FLI1 using a targeted, non viral formulation inhibits growth in a disseminated murine model of Ewing's sarcoma. Mol Ther 2005, 11: S28.
30. Schiffelers, R.M., Mixson, A.J., Ansari, A.M. et al. Transporting silence: Design of carriers for siRNA to angiogenic endothelium. J Control Release 2005, 109: 5-14.
31. Kim, S.H., Jeong, J.H., Cho, K.C., Kim, S.W., Park, T.G. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J Control Release 2005, 104: 223-32.
32. Kushibiki, T., Nagata-Nakajima, N., Sugai, M., Shimizu, A., Tabata, Y. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J Control Release 2005, 105: 318-31.
33. Moriguchi, R., Kogure, K., Akita, H. et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 2005, 301: 277-85.
34. Woodle, M.C., Lu, P.Y. Nanoparticles deliver RNAi therapy. Nanotoday 2005, 97: 345-56.
35. Kakizawa, Y., Furukawa, S., Kataoka, K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release 2004, 97: 345-56.
36. Farra, R., Voinivic, D., Rubessa, F. et al. Characterization of liposomes for the delivery of siRNAs in the treatment of coronary restenosis. Eur J Pharm Sci 2005, 25(Suppl. 1): S99.
37. Grassi, G., Crevatin, A., Farra, R. et al. Rheological properties of aqueous Pluronic-Alginate systems containing liposomes. J Colloid Interface Sci 2006, In press.
38. Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432: 173-8.
39. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.P., Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004, 14: 4975-7.
40. 2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol 2004, 37: 691-8.
41. MacLennan, D.H., Kranias, E.G. Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003, 4: 566-77.
42. 2+ ATPase 2 (SERCA2) activity: Cell biological implications. Cell Calcium 2005, 38: 291-302.
43. Meyer, M., Schillinger, W., Pieske, B. et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995, 92: 778-84.
44. 2+ signaling mechanism in cardiac myocytes. Proc Natl Acad Sci USA 2004, 101: 16683-8.
45. Hunton, D.L., Lucchesi, P.A., Pang, Y., Cheng, X., Dell'Italia, L.J., Marchase, R.B. Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem 2002, 277: 14266-73.
46. 2+ exchanger expression but does not prevent contraction of neonatal cardiomyocytes. J Mol Cell Cardiol 2005, 38: 647-54.
47. Natarajan, R., Salloum, F.N., Fisher, B.J., Kukreja, R.C., Fowler, A.A., III. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006, 98: 133-40.
48. Yin, C., Xi, L., Wang, X., Eapen, M., Kukreja, R.C. Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. J Mol Cell Cardiol 2005, 39: 681-9.
49. Davidson, S.M., Stephanou, A., Latchman, D.S. FLIP protects cardiomyocytes from apoptosis induced by simulated ischemia/reoxygenation, as demonstrated by short hairpin-induced (shRNA) silencing of FLIP mRNA. J Mol Cell Cardiol 2003, 35: 1359-64.
50. Dec, G.W., Fuster, V. Idiopathic dilated cardiomyopathy. New Engl J Med 1994, 331: 1564-75.
51. Sole, M.J., Liu, P. Viral myocarditis: A paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993, 22: 99A-105A.
52. Kandolf, R., Ameis, D., Kirschner, P., Canu, A., Hofschneider, P.M. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987, 84: 6272-6.
53. Kandolf, R., Klingel, K., Mertsching, H. et al. Molecular studies on enteroviral heart disease: Patterns of acute and persistent infections. Eur Heart J 1991, 12(Suppl. D): 49-55.
54. Klingel, K., Rieger, P., Mall, G., Selinka, H.C., Huber, M., Kandolf, R. Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: Identification of target cells and cytopathic effects. Lab Invest 1998, 78: 1227-37.
55. Klingel, K., Hohenadl, C., Canu, A. et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: Quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992, 89: 314-8.
56. Ayach, B., Fuse, K., Martino, T., Liu, P. Dissecting mechanisms of innate and acquired immunity in myocarditis. Curr Opin Cardiol 2003, 18: 175-81.
57. Mason, J.W., O'Connell, J.B., Herskowitz, A. et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. New Engl J Med 1995, 333: 269-75.
58. Klingel, K., Schnorr, J.J., Sauter, M., Szalay, G., Kandolf, R. Beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis. Am J Pathol 2003, 162: 1709-20.
59. Yuan, J., Cheung, P.K., Zhang, H.M., Chau, D., Yang, D. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J Virol 2005, 79: 2151-9.
60. Ahn, J., Jun, E.S., Lee, H.S. et al. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol 2005, 79: 8620-4.
61. Racchi, G., Klingel, K., Kandolf, R., Rainaldi, G., Mercatanti, A., Grassi, G. siRNAs targeted against coxsackieviruses B3 genome down regulate virus proliferation thus showing their potential use in the prevention of viral myocarditis. 13th Annu Cong Eur Soc Gene Ther (Oct 29-Nov 1, Prague) 2005.
62. Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., Wessely, R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 2005, 111: 1583-92.
63. Rueckert, R.R. The enteroviruses. In: Fundamental Virology. Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.). New York, Raven Press, 1996, 477-522.
64. Krausslich, H.G., Nicklin, M.J., Toyoda, H., Etchison, D., Wimmer, E. Poliovirus proteinase 2A induces cleavage of eukaryotic initiation factor 4F polypeptide p220. J Virol 1987, 61: 2711-8.
65. Kerekatte, V., Keiper, B.D., Badorff, C., Cai, A., Knowlton, K.U., Rhoads, R.E. Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: Another mechanism for host protein synthesis shutoff? J Virol 1999, 73: 709-17.
66. Badorff, C., Lee, G.H., Lamphear, B.J. et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999, 5: 320-6.
67. Liu, P.P., Mason, J.W. Advances in the understanding of myocarditis. Circulation 2001, 104: 1076-82.
68. Xiong, D., Lee, G.H., Badorff, C. et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med 2002, 8: 872-7.
69. Werk, D., Schubert, S., Lindig, V. et al. Developing an effective RNA interference strategy against a plus-strand RNA virus: Silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor. Biol Chem 2005, 386: 857-63.
70. Blaschke, F., Bruemmer, D., Yin, F. et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004, 110: 579-87.
71. Bennett, M.R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999, 41: 361-8.
72. Walker, T., Wendel, H.P., Tetzloff, L., Heidenreich, O., Ziemer, G. Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs. Eur J Cardiothorac Surg 2005, 28: 816-20.
73. Califf, R.M. Restenosis: The cost to society. Am Heart J 1995, 130: 680-4.
74. Labinaz, M., Pels, K., Hoffert, C., Aggarwal, S., O'Brien, E.R. Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries. Cardiovasc Res 1999, 41: 255-66.
75. Kearney, M., Pieczek, A., Haley, L. et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997, 95: 1998-2002.
76. Morice, M.C., Serruys, P.W., Sousa, J.E. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New Engl J Med 2002, 346: 1773-80.
77. Colombo, A., Drzewiecki, J., Banning, A. et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108: 788-94.
78. Colombo, A., Moses, J.W., Morice, M.C. et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004, 109: 1244-9.
79. Holmes, D.R., Jr., Leon, M.B., Moses, J.W. et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004, 109: 634-40.
80. Grassi, G., Dapas, R., Farra, R. et al. siRNAs targeted against cyclin E1 and E2F1 down regulate coronary smooth muscle cells proliferation thus showing their potential use in the prevention of in-stent restenosis. 13th Annu Cong Eur Soc Gene Ther (Oct 29-Nov 1, Prague) 2005, Abst p004.
81. Werth, D., Heidenreich, O., Nordheim, A., Herdeg, C., Grassi, G. siRNAs targeting serum response factor as potential tools to interfere with in-stent restenosis. 12th Annu Cong Eur Soc Gene Ther (Nov 4-7, Tampere) 2004, Abst P 163.
82. Grassi, G., Schneider, A., Engel, S., Racchi, G., Kandolf, R., Kuhn, A. Hammerhead ribozymes targeted against cyclin E and E2F1 co-operate to down regulate coronary smooth muscle cells proliferation. J Gene Med 2005, 7: 1223-4.
83. Grassi, G., Dawson, P., Guarnieri, G., Kandolf, R., Grassi M. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases. Curr Pharm Biotechnol 2004, 5: 369-86.
84. Poliseno, L., Evangelista, M., Ricci, F., Bonotti, A., Nannipieri, M., Rainaldi, G. Identification of active siRNAs against IGF-IR of porcine coronary smooth muscle cells in a heterologous cell line. Int J Mol Med 2005, 15: 713-8.
85. Poliseno, L., Cecchettini, A., Mariani, L. et al. Resting smooth muscle cells as a model for studying vascular cell activation. Tissue Cell 2006, 38: 111-20.
86. Poliseno, L., Evangelista, M., Giacca, M., Rainaldi, G. The analysis of dose response curve cimes is useful for the assembly of multi-siRNAs expressing cassettes. Gene Ther Mol Biol 2006, 10: 101-8.